CLICK HERE FOR BRIUMVI® (ublituximab-xiiy) PRESCRIBING INFORMATION

FIERCELY FOCUSED

Product Patents

In accordance with 35 U.S.C. § 287(a), the following listing may be used, in conjunction with the FDA-approved prescribing information, to determine the U.S. patents for the products listed below that are marketed in the U.S.; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive.

PRODUCT                                                     U.S. Patent No.

UKONIQTM (umbralisib) Tablets:                 9,150,579

……………………..00000000………………………………………………..9,669,033

…………………….00000000…………………………………………………9,969,740

……………………..00000000……………………………………………….10,072,013

……………………..00000000……………………………………………….10,414,773

……………………….00000000……………………………………………..10,570,142